{"product_id":"quipthomemedical-bcg-matrix","title":"Quipt Home Medical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuipt Home Medical’s preliminary BCG Matrix highlights clear product dynamics—emerging Stars in home respiratory devices, steady Cash Cows from established consumables, and potential Question Marks in remote-monitoring tech needing scale. This preview teases strategic positioning and resource implications; purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment and product decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Resupply Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutomated Resupply Program is a Star: high-growth, subscription-driven segment for Quipt Home Medical as patients shift to recurring healthcare; US oxygen concentrator subscriptions grew ~28% YoY in 2024, fueling demand.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the program captured a large share of the respiratory resupply niche—Quipt reports ~18% market share in resupply software-enabled respiratory services—driven by API integrations and remote monitoring.\u003c\/p\u003e\n\u003cp\u003eIt needs continuous capex in logistics and digital stack—estimated $12–18M cumulative 2023–2025—to scale fulfillment and reduce churn; unit economics improve as ARPU rises.\u003c\/p\u003e\n\u003cp\u003eWith continued investment, the program is positioned to move from high-growth Star to primary cash generator as retention and margins rise beyond year 3.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSleep Apnea and CPAP Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSleep therapy is a high-growth US market, with OSA (obstructive sleep apnea) diagnoses up ~12% annually and CPAP device demand rising—US CPAP sales topped $1.9B in 2024. Quipt Home Medical holds a leading share in CPAP setups, claiming ~15% market share via turnkey patient setups and 24\/7 clinical support. Competition is intense, yet recurring replacement cycles (average device life 3–5 years) and 18% expected CAGR keep this unit a top performer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemote Patient Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRemote Patient Monitoring (RPM) aligns with the shift to value-based care and home-based management; the global RPM market hit $1.9B in 2024 and is forecast to reach $6.5B by 2030 (CAGR ~22%), so Quipt’s push targets a fast-growing segment. Quipt has aggressively invested to win share early, spending an estimated $45–60M since 2022 on tech, partnerships, and regulatory compliance to scale devices and platforms. This tech-heavy move consumes cash now—Q1 2025 R\u0026amp;D and capex rose 80% YoY—but can secure market leadership across post-acute care if successful. Given rising Medicare RPM reimbursements (2024 rates up ~12%), Quipt’s timing aims to convert early investment into durable revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Regional Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuipt Home Medical uses targeted regional acquisitions to grab market share in fast-growing areas; 2024 deals grew top-line regional sales by ~28% and added 15k new patient accounts.\u003c\/p\u003e\n\u003cp\u003eThese units enter as Stars in the BCG matrix, needing capital for rebranding and systems integration—CapEx and integration costs averaged $3.6M per deal in 2024.\u003c\/p\u003e\n\u003cp\u003eOnce stabilized, the acquisitions widen Quipt’s footprint and enable scaling of specialized services, contributing ~12% of company-wide adjusted EBITDA in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: 28% revenue lift from acquisitions\u003c\/li\u003e\n\u003cli\u003e15,000 new patient accounts added\u003c\/li\u003e\n\u003cli\u003e$3.6M average integration CapEx per deal\u003c\/li\u003e\n\u003cli\u003eContributed ~12% to adjusted EBITDA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Acuity Respiratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-acuity respiratory services for complex chronic patients are growing ~12–15% annually as hospital-at-home expands; Quipt holds a top-3 share in this niche and reports ~25–30% gross margins versus 10–15% on standard equipment (2024 internal results).\u003c\/p\u003e\n\u003cp\u003eTo keep leadership and capture a projected +20% patient-census increase by 2026, Quipt must keep hiring and training respiratory therapists and clinical nurses; staff costs will rise ~8–10% but protect margin and reimbursement gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e+12–15% annual market growth\u003c\/li\u003e\n\u003cli\u003eQuipt: top-3 niche share\u003c\/li\u003e\n\u003cli\u003eMargins: 25–30% vs 10–15%\u003c\/li\u003e\n\u003cli\u003ePatient census +20% by 2026\u003c\/li\u003e\n\u003cli\u003eStaff cost rise ~8–10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisitions + RPM fuel 28% revenue surge; resupply\/CPAP share gains, 25–30% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Automated Resupply, Sleep (CPAP), RPM, Regional Acquisitions, High‑acuity Respiratory show high growth, strong shares, and heavy capex; together they drove ~28% revenue lift from acquisitions, $45–60M RPM investment since 2022, 18% resupply share (2025), 15% CPAP share (2024), 25–30% margins in high‑acuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcq rev lift 2024\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPM spend\u003c\/td\u003e\n\u003ctd\u003e$45–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResupply share\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP share\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh‑acuity margin\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Quipt Home Medical products with strategic recommendations to invest, hold, or divest per quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing Quipt Home Medical units in a BCG Matrix to quickly identify stars, cash cows, dogs, and question marks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStationary Oxygen Concentrators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing oxygen therapy is a mature US market (~$4.6B 2024), where Quipt Home Medical holds a dominant, stable share in its service regions, producing steady rental and service revenue streams.\u003c\/p\u003e\n\u003cp\u003eStationary oxygen concentrators deliver consistent cash flow with low incremental marketing spend; 2024 gross margins for durable medical equipment averaged ~38%, and Quipt reports similar high margins.\u003c\/p\u003e\n\u003cp\u003eThese cash flows fund R\u0026amp;D and expansion into high-growth medtech; in 2024 Quipt reinvested a reported ~15–20% of revenue into product development and acquisitions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring CPAP Masks and Tubing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReplacement CPAP masks and tubing generate steady, high-volume revenue—US CPAP supply spending was about $1.1B in 2024—with low growth but high loyalty as patients replace supplies every 3–6 months. \u003c\/p\u003e\n\u003cp\u003eQuipt already owns the patient relationship, so customer acquisition costs are minimal; retention rates exceed 70% in 2024 surveys, keeping margins high. \u003c\/p\u003e\n\u003cp\u003eThese predictable cash flows cover interest on Quipt’s 2024 debt (total long-term debt ~$85M) and fund R\u0026amp;D into new mask tech. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Nebulizer Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNebulizers are a cash cow for Quipt Home Medical, holding a dominant home-use share—about 35% US market in 2024—and generating steady revenue with ~18% gross margins and roughly $45–50M annual sales from the category. The market is mature, with ~2% CAGR expected through 2028, so growth is low but predictable. Minimal capex is needed to sustain production and service, freeing cash for higher-growth lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Hospital Bed Rentals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHome hospital bed rentals are a mature, high-cash business for Quipt, with U.S. demand rising 3.2% annually and 2024 market size ~ $1.1B; aging population (16% of U.S. 65+ in 2024) sustains steady orders.\u003c\/p\u003e\n\u003cp\u003eQuipt’s large inventory and regional network yield utilization \u0026gt;78% and gross margins ~42% in 2024, producing predictable cash flow and short payback on assets.\u003c\/p\u003e\n\u003cp\u003eLow overhead—centralized logistics and service teams—keeps operating margin near 18%, making this a reliable cash cow funding growth areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth ~3.2% CAGR\u003c\/li\u003e\n\u003cli\u003e2024 U.S. HHC bed market ≈ $1.1B\u003c\/li\u003e\n\u003cli\u003eUtilization \u0026gt;78%\u003c\/li\u003e\n\u003cli\u003eGross margin ~42%, operating margin ~18%\u003c\/li\u003e\n\u003cli\u003eHigh cash conversion, short asset payback\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Southeastern US Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eQuipt Home Medical’s established Southeastern US operations hold high regional market share and maturity, generating stable EBITDA margins near 22% in 2024 and low incremental CAPEX thanks to optimized logistics and referral networks.\u003c\/p\u003e\n\u003cp\u003eThese hubs require minimal new investment to sustain profitability, producing free cash flow that funded 48% of the company’s 2024 expansion spend into Western markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share, mature region\u003c\/li\u003e\n\u003cli\u003eEBITDA ≈ 22% (2024)\u003c\/li\u003e\n\u003cli\u003eLow incremental CAPEX; optimized logistics\u003c\/li\u003e\n\u003cli\u003eFunded 48% of 2024 West expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuipt’s high-margin 2024 cash engine funds R\u0026amp;D, west expansion; EBITDA ~22%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuipt’s mature home-oxygen, nebulizer, CPAP-supplies, beds, and SE hubs generated stable high-margin cash flow in 2024 (gross margins 18–42%, EBITDA ~22%), funding 15–20% R\u0026amp;D and 48% of west expansion; utilization \u0026gt;78%, long-term debt ~$85M, cash funds interest and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margins\u003c\/td\u003e\n\u003ctd\u003e18–42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eQuipt Home Medical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing on this page is the final Quipt Home Medical BCG Matrix you’ll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747932385657,"sku":"quipthomemedical-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/quipthomemedical-bcg-matrix.png?v=1772202985","url":"https:\/\/matrixbcg.com\/products\/quipthomemedical-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}